JP2020506700A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506700A5 JP2020506700A5 JP2019541338A JP2019541338A JP2020506700A5 JP 2020506700 A5 JP2020506700 A5 JP 2020506700A5 JP 2019541338 A JP2019541338 A JP 2019541338A JP 2019541338 A JP2019541338 A JP 2019541338A JP 2020506700 A5 JP2020506700 A5 JP 2020506700A5
- Authority
- JP
- Japan
- Prior art keywords
- membrane protein
- chimeric membrane
- cell
- antigen
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010052285 Membrane Proteins Proteins 0.000 claims 105
- 102000018697 Membrane Proteins Human genes 0.000 claims 101
- 239000000427 antigen Substances 0.000 claims 59
- 108091007433 antigens Proteins 0.000 claims 59
- 102000036639 antigens Human genes 0.000 claims 59
- 238000006467 substitution reaction Methods 0.000 claims 56
- 125000003275 alpha amino acid group Chemical group 0.000 claims 46
- 210000004027 cell Anatomy 0.000 claims 34
- 239000003112 inhibitor Substances 0.000 claims 32
- 238000012217 deletion Methods 0.000 claims 28
- 230000037430 deletion Effects 0.000 claims 28
- 238000003780 insertion Methods 0.000 claims 28
- 230000037431 insertion Effects 0.000 claims 28
- 206010028980 Neoplasm Diseases 0.000 claims 23
- 230000003834 intracellular effect Effects 0.000 claims 23
- 150000007523 nucleic acids Chemical class 0.000 claims 18
- 108020004707 nucleic acids Proteins 0.000 claims 17
- 102000039446 nucleic acids Human genes 0.000 claims 17
- 206010025323 Lymphomas Diseases 0.000 claims 14
- 102000004169 proteins and genes Human genes 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 12
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 12
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 12
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 12
- -1 ICOS (CD278) Proteins 0.000 claims 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 210000000822 natural killer cell Anatomy 0.000 claims 6
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 5
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 5
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 5
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 5
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 5
- 208000003950 B-cell lymphoma Diseases 0.000 claims 4
- 108091033409 CRISPR Proteins 0.000 claims 4
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims 4
- 108091027967 Small hairpin RNA Proteins 0.000 claims 4
- 108020004459 Small interfering RNA Proteins 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 4
- 238000010362 genome editing Methods 0.000 claims 4
- 239000004055 small Interfering RNA Substances 0.000 claims 4
- 102100038449 Claudin-6 Human genes 0.000 claims 3
- 101000882898 Homo sapiens Claudin-6 Proteins 0.000 claims 3
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims 3
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims 3
- 102100032818 Integrin alpha-4 Human genes 0.000 claims 3
- 102100032816 Integrin alpha-6 Human genes 0.000 claims 3
- 102000003735 Mesothelin Human genes 0.000 claims 3
- 108090000015 Mesothelin Proteins 0.000 claims 3
- 102100029197 SLAM family member 6 Human genes 0.000 claims 3
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- 238000011301 standard therapy Methods 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 102100024263 CD160 antigen Human genes 0.000 claims 2
- 102100038077 CD226 antigen Human genes 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 102100027217 CD82 antigen Human genes 0.000 claims 2
- 102100035793 CD83 antigen Human genes 0.000 claims 2
- 238000010354 CRISPR gene editing Methods 0.000 claims 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 2
- 102100038083 Endosialin Human genes 0.000 claims 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims 2
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 2
- 101000884275 Homo sapiens Endosialin Proteins 0.000 claims 2
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 claims 2
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims 2
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 claims 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 2
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims 2
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 claims 2
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims 2
- 101000633782 Homo sapiens SLAM family member 8 Proteins 0.000 claims 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 2
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 102100025323 Integrin alpha-1 Human genes 0.000 claims 2
- 102100022341 Integrin alpha-E Human genes 0.000 claims 2
- 102100022339 Integrin alpha-L Human genes 0.000 claims 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims 2
- 102100022297 Integrin alpha-X Human genes 0.000 claims 2
- 102100025304 Integrin beta-1 Human genes 0.000 claims 2
- 102100025390 Integrin beta-2 Human genes 0.000 claims 2
- 108010002586 Interleukin-7 Proteins 0.000 claims 2
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 102000014128 RANK Ligand Human genes 0.000 claims 2
- 108010025832 RANK Ligand Proteins 0.000 claims 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
- 102100029216 SLAM family member 5 Human genes 0.000 claims 2
- 102100029214 SLAM family member 8 Human genes 0.000 claims 2
- 102100027744 Semaphorin-4D Human genes 0.000 claims 2
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 2
- 238000010459 TALEN Methods 0.000 claims 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000036039 immunity Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000002250 progressing effect Effects 0.000 claims 2
- 239000002924 silencing RNA Substances 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims 1
- 102100022464 5'-nucleotidase Human genes 0.000 claims 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 102000017918 ADRB3 Human genes 0.000 claims 1
- 108060003355 ADRB3 Proteins 0.000 claims 1
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims 1
- 208000017726 ALK-positive large B-cell lymphoma Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims 1
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 claims 1
- 102100023003 Ankyrin repeat domain-containing protein 30A Human genes 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 1
- 108700012439 CA9 Proteins 0.000 claims 1
- 108010056102 CD100 antigen Proteins 0.000 claims 1
- 108010017009 CD11b Antigen Proteins 0.000 claims 1
- 102100038078 CD276 antigen Human genes 0.000 claims 1
- 108010058905 CD44v6 antigen Proteins 0.000 claims 1
- 108010062802 CD66 antigens Proteins 0.000 claims 1
- 102100027221 CD81 antigen Human genes 0.000 claims 1
- 101710139831 CD82 antigen Proteins 0.000 claims 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 1
- 102000013392 Carboxylesterase Human genes 0.000 claims 1
- 108010051152 Carboxylesterase Proteins 0.000 claims 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 102100035167 Coiled-coil domain-containing protein 54 Human genes 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 1
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 claims 1
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 claims 1
- 208000017815 Dendritic cell tumor Diseases 0.000 claims 1
- 101100095895 Drosophila melanogaster sle gene Proteins 0.000 claims 1
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 102000012804 EPCAM Human genes 0.000 claims 1
- 101150084967 EPCAM gene Proteins 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 101000585551 Equus caballus Pregnancy-associated glycoprotein Proteins 0.000 claims 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims 1
- 102000010449 Folate receptor beta Human genes 0.000 claims 1
- 108050001930 Folate receptor beta Proteins 0.000 claims 1
- 102100036939 G-protein coupled receptor 20 Human genes 0.000 claims 1
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 claims 1
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 claims 1
- 101710088083 Glomulin Proteins 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 claims 1
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 claims 1
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 claims 1
- 101000757191 Homo sapiens Ankyrin repeat domain-containing protein 30A Proteins 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims 1
- 101000936083 Homo sapiens Baculoviral IAP repeat-containing protein 7 Proteins 0.000 claims 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims 1
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101000737052 Homo sapiens Coiled-coil domain-containing protein 54 Proteins 0.000 claims 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 1
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 claims 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 claims 1
- 101001071355 Homo sapiens G-protein coupled receptor 20 Proteins 0.000 claims 1
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 claims 1
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 1
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 claims 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 1
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 claims 1
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 claims 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 1
- 101000984196 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 5 Proteins 0.000 claims 1
- 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 claims 1
- 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 claims 1
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 claims 1
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 claims 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 1
- 101000721757 Homo sapiens Olfactory receptor 51E2 Proteins 0.000 claims 1
- 101000589399 Homo sapiens Pannexin-3 Proteins 0.000 claims 1
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 claims 1
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 claims 1
- 101000691463 Homo sapiens Placenta-specific protein 1 Proteins 0.000 claims 1
- 101001064779 Homo sapiens Plexin domain-containing protein 2 Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims 1
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 1
- 101000824971 Homo sapiens Sperm surface protein Sp17 Proteins 0.000 claims 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 claims 1
- 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 claims 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 1
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims 1
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 claims 1
- 101000808105 Homo sapiens Uroplakin-2 Proteins 0.000 claims 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 1
- 108010041100 Integrin alpha6 Proteins 0.000 claims 1
- 108010030465 Integrin alpha6beta1 Proteins 0.000 claims 1
- 102100033016 Integrin beta-7 Human genes 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 1
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 claims 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims 1
- 206010023774 Large cell lung cancer Diseases 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 108010028275 Leukocyte Elastase Proteins 0.000 claims 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 1
- 102000016799 Leukocyte elastase Human genes 0.000 claims 1
- 102100025574 Leukocyte immunoglobulin-like receptor subfamily A member 5 Human genes 0.000 claims 1
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 claims 1
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 claims 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 1
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 1
- 101100182730 Mus musculus Ly6k gene Proteins 0.000 claims 1
- 101100236305 Mus musculus Ly9 gene Proteins 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 108091008877 NK cell receptors Proteins 0.000 claims 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 1
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims 1
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 108090000028 Neprilysin Proteins 0.000 claims 1
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- KUIFHYPNNRVEKZ-VIJRYAKMSA-N O-(N-acetyl-alpha-D-galactosaminyl)-L-threonine Chemical compound OC(=O)[C@@H](N)[C@@H](C)O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O KUIFHYPNNRVEKZ-VIJRYAKMSA-N 0.000 claims 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims 1
- 102100025128 Olfactory receptor 51E2 Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102100032364 Pannexin-3 Human genes 0.000 claims 1
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 claims 1
- 102100026181 Placenta-specific protein 1 Human genes 0.000 claims 1
- 208000033014 Plasma cell tumor Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 1
- 102100031889 Plexin domain-containing protein 2 Human genes 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 1
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 claims 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100029198 SLAM family member 7 Human genes 0.000 claims 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims 1
- 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 101150057140 TACSTD1 gene Proteins 0.000 claims 1
- 102100029337 Thyrotropin receptor Human genes 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 1
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 1
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100038851 Uroplakin-2 Human genes 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000007969 cellular immunity Effects 0.000 claims 1
- 210000000038 chest Anatomy 0.000 claims 1
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 102000003675 cytokine receptors Human genes 0.000 claims 1
- 108010057085 cytokine receptors Proteins 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 208000010963 diffuse large B-cell lymphoma with chronic inflammation Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims 1
- 102000006815 folate receptor Human genes 0.000 claims 1
- 108020005243 folate receptor Proteins 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 1
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000009546 lung large cell carcinoma Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 1
- 230000001589 lymphoproliferative effect Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000006178 malignant mesothelioma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000005282 malignant pleural mesothelioma Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 208000015325 multicentric Castleman disease Diseases 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 208000010626 plasma cell neoplasm Diseases 0.000 claims 1
- 208000007525 plasmablastic lymphoma Diseases 0.000 claims 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 208000019694 serous adenocarcinoma Diseases 0.000 claims 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 230000003393 splenic effect Effects 0.000 claims 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023023427A JP2023071774A (ja) | 2017-01-31 | 2023-02-17 | 多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762452601P | 2017-01-31 | 2017-01-31 | |
| US62/452,601 | 2017-01-31 | ||
| PCT/US2018/016139 WO2018144535A1 (en) | 2017-01-31 | 2018-01-31 | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023023427A Division JP2023071774A (ja) | 2017-01-31 | 2023-02-17 | 多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020506700A JP2020506700A (ja) | 2020-03-05 |
| JP2020506700A5 true JP2020506700A5 (enExample) | 2021-03-11 |
Family
ID=61274328
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541338A Pending JP2020506700A (ja) | 2017-01-31 | 2018-01-31 | 多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療 |
| JP2023023427A Pending JP2023071774A (ja) | 2017-01-31 | 2023-02-17 | 多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023023427A Pending JP2023071774A (ja) | 2017-01-31 | 2023-02-17 | 多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20190375815A1 (enExample) |
| EP (1) | EP3577134A1 (enExample) |
| JP (2) | JP2020506700A (enExample) |
| CN (1) | CN110582509A (enExample) |
| WO (1) | WO2018144535A1 (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
| LT2958943T (lt) | 2013-02-20 | 2020-01-27 | The Trustees Of The University Of Pennsylvania | Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių |
| EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| WO2015112626A1 (en) | 2014-01-21 | 2015-07-30 | June Carl H | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| US9777061B2 (en) | 2014-07-21 | 2017-10-03 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
| MY181834A (en) | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| SG11201700770PA (en) | 2014-08-19 | 2017-03-30 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| AU2015330898B2 (en) | 2014-10-08 | 2022-03-10 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| MX2017012939A (es) | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| AU2016249005B2 (en) | 2015-04-17 | 2022-06-16 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| WO2017015427A1 (en) | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| US11667691B2 (en) * | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| CN116334205A (zh) | 2015-09-03 | 2023-06-27 | 诺华股份有限公司 | 预测细胞因子释放综合征的生物标志物 |
| CN108699557B (zh) | 2015-12-04 | 2025-08-15 | 诺华股份有限公司 | 用于免疫肿瘤学的组合物和方法 |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2018067992A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
| EP3568466A4 (en) | 2017-01-10 | 2020-07-15 | The General Hospital Corporation | TARGETED T CELLS WITH CYTOTOXICITY TO IMMUNOSUPPRESSIVE CELLS |
| EP3574005B1 (en) | 2017-01-26 | 2021-12-15 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| KR20190130608A (ko) | 2017-03-22 | 2019-11-22 | 노파르티스 아게 | 면역종양학을 위한 조성물 및 방법 |
| CA3059444A1 (en) | 2017-04-14 | 2018-10-18 | The General Hospital Corporation | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| KR20200086278A (ko) | 2017-10-18 | 2020-07-16 | 노파르티스 아게 | 선택적 단백질 분해를 위한 조성물 및 방법 |
| IL275040B2 (en) * | 2017-12-05 | 2026-05-01 | The Medical Res Infrastructure And Health Services Fund Of The Tel Aviv Medical Center | T cells containing two chimeric receptors for different antigens and their use |
| US11944644B2 (en) | 2017-12-05 | 2024-04-02 | The Medical Research Infrastructure And Health Services Fund Of The Tel Aviv Medical Center | T-cells comprising anti-CD38 and anti-CD138 chimeric antigen receptors and uses thereof |
| CN112218651A (zh) | 2018-01-08 | 2021-01-12 | 诺华公司 | 用于与嵌合抗原受体疗法组合的免疫增强rna |
| WO2019157533A1 (en) * | 2018-02-12 | 2019-08-15 | The General Hospital Corporation | Chimeric antigen receptors targeting the tumor microenvironment |
| AU2019284911B2 (en) | 2018-06-13 | 2026-04-09 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
| KR20210098940A (ko) | 2018-11-27 | 2021-08-11 | 듀크 유니버시티 | Ebv 관련 암의 치료를 위한 항-lmp2 tcr-t 세포 요법 |
| EP3895052A4 (en) | 2018-12-14 | 2022-10-26 | 2seventy bio, Inc. | DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES |
| AU2020208110A1 (en) * | 2019-01-14 | 2021-07-15 | Nanjing Legend Biotech Co., Ltd. | Chimeric receptor polypeptides and uses thereof |
| EP3958875A4 (en) * | 2019-04-25 | 2023-05-10 | Purdue Research Foundation | MANIPULATED NATURAL KILLER CELLS TARGETING PURINGERIC SIGNALING, THEIR CONSTRUCTS AND METHODS OF USE |
| BR112021022795A2 (pt) * | 2019-05-16 | 2022-01-18 | Memorial Sloan Kettering Cancer Center | Composição polipeptídica compreendendo cars de mesotelina , células imunorresponsivas e seu método de produção, composição farmacêutica, composição de ácido nucleico, vetor e kit compreendendo composição de polipeptídeo |
| AU2020296197A1 (en) * | 2019-06-21 | 2022-01-20 | Shattuck Labs, Inc. | Chimeric protein expressing T-cells |
| EP4065158A2 (en) | 2019-11-26 | 2022-10-05 | Novartis AG | Chimeric antigen receptors binding bcma and cd19 and uses thereof |
| KR20220104217A (ko) | 2019-11-26 | 2022-07-26 | 노파르티스 아게 | Cd19 및 cd22 키메라 항원 수용체 및 이의 용도 |
| WO2021119489A1 (en) | 2019-12-11 | 2021-06-17 | A2 Biotherapeutics, Inc. | Lilrb1-based chimeric antigen receptor |
| CN115397845A (zh) * | 2020-02-20 | 2022-11-25 | 森迪生物科学公司 | 抑制性嵌合受体架构 |
| CN111484563B (zh) * | 2020-04-30 | 2020-11-10 | 徐州医科大学附属医院 | 一种抗cd38嵌合抗原受体及其应用 |
| CN115768880A (zh) * | 2020-05-06 | 2023-03-07 | 亘喜生物科技（上海）有限公司 | 用于t细胞工程化的组合物和方法 |
| CA3187163A1 (en) * | 2020-05-07 | 2021-11-11 | China Immunotech (Beijing) Biotechnology Co., Ltd | Improved t cell receptor-costimulatory molecule chimera |
| JP7591772B2 (ja) * | 2020-05-25 | 2024-11-29 | ブリスター イムノテック リミテッド | 強化された合成ｔ細胞受容体及び抗原受容体 |
| KR20230040364A (ko) * | 2020-07-27 | 2023-03-22 | 센터 포 엑설런스 인 몰레큘러 셀 사이언스, 차이니즈 아카데미 오브 사이언시스 | 키메라 항원 수용체 및 이의 용도 |
| CN113980136B (zh) * | 2020-07-27 | 2023-08-22 | 中国科学院分子细胞科学卓越创新中心 | 一种包含具有Y/F突变的CD3ε胞内区的嵌合抗原受体及其用途 |
| CN113980137B (zh) * | 2020-07-27 | 2023-08-22 | 中国科学院分子细胞科学卓越创新中心 | 一种包含CD3ε胞内碱性氨基酸富集区基序的嵌合抗原受体及其用途 |
| EP4058474B1 (en) | 2020-08-20 | 2024-05-08 | A2 Biotherapeutics, Inc. | Compositions and methods for treating egfr positive cancers |
| WO2022040454A1 (en) | 2020-08-20 | 2022-02-24 | A2 Biotherapeutics, Inc. | Compositions and methods for treating mesothelin positive cancers |
| EP4097486A4 (en) | 2020-08-20 | 2023-09-06 | A2 Biotherapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF POSITIVE CANCERS AT CEACAM |
| CN113980138B (zh) * | 2021-08-11 | 2023-08-11 | 卡瑞济(北京)生命科技有限公司 | EphA2嵌合抗原受体以及其用途 |
| CN115806625B (zh) * | 2021-09-15 | 2023-08-04 | 广州百暨基因科技有限公司 | T细胞限定表达的嵌合抗原受体及其应用 |
| IL316032A (en) * | 2022-04-08 | 2024-11-01 | Regeneron Pharma | Multicomponent receptor and signaling complexes |
| US20260091114A1 (en) * | 2022-09-14 | 2026-04-02 | Fred Hutchinson Cancer Center | Chimeric antigen receptors binding nectin-4 |
| CN117402262A (zh) * | 2022-10-19 | 2024-01-16 | 上海君赛生物科技有限公司 | 基于lag3的嵌合免疫细胞辅助受体及其用途 |
| CN116041545A (zh) * | 2022-12-12 | 2023-05-02 | 南方医科大学 | 一种靶向荧光素或生物素的通用型car及其应用 |
| WO2024133052A1 (en) * | 2022-12-19 | 2024-06-27 | Universität Basel Vizerektorat Forschung | T-cell receptor fusion protein |
| CN116478929B (zh) * | 2023-04-07 | 2024-06-28 | 科弈(浙江)药业科技有限公司 | 靶向bcma和cd19的双特异性car-t细胞 |
| KR20260017010A (ko) * | 2023-04-24 | 2026-02-04 | 엘피스 바이오파마슈티컬즈 | 장갑 항-b7h3 car-t 세포 및 암 치료에 있어서의 그 용도 |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025162379A1 (zh) * | 2024-02-01 | 2025-08-07 | 深圳市济因生物科技有限公司 | 一种多肽及包含所述多肽基因的病毒载体 |
Family Cites Families (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US504048A (en) | 1893-08-29 | Sulky | ||
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4851332A (en) | 1985-04-01 | 1989-07-25 | Sloan-Kettering Institute For Cancer Research | Choriocarcinoma monoclonal antibodies and antibody panels |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| JP4157160B2 (ja) | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | 改変抗体可変領域の調製のための方法 |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| EP0679660A4 (en) | 1993-11-16 | 2000-08-16 | Pola Chem Ind Inc | MONOCLONAL ANTIBODY AGAINST HUMAN TYROSINASE |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| WO1995029193A2 (en) | 1994-04-22 | 1995-11-02 | The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services | Melanoma antigens |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| JP3066983B2 (ja) | 1995-01-18 | 2000-07-17 | ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 膜結合ｃｄ３０抗原の蛋白質分解性開裂及び遊離を防ぐ抗ｃｄ３０抗体 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| DE19608769C1 (de) | 1996-03-07 | 1997-04-10 | Univ Eberhard Karls | Antikörper BV10A4H2 |
| DE69703121D1 (de) | 1996-10-25 | 2000-10-19 | Us Health | Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit |
| US6803448B1 (en) | 1998-07-22 | 2004-10-12 | Vanderbilt University | GBS toxin receptor |
| US6528481B1 (en) | 1999-02-16 | 2003-03-04 | The Burnam Institute | NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods |
| PL211786B1 (pl) | 1999-08-17 | 2012-06-29 | Apoxis Sa | Zastosowanie przeciwciała oraz polipeptydu |
| DE60038252T2 (de) | 1999-09-30 | 2009-03-19 | Kyowa Hakko Kogyo Co., Ltd. | Menschlicher Antikörper gegen Gangliosid GD3 für die Transplantationskomplentarität bestimmende Region und Derivate des Antikörpers gegen das Gangliosid GD3 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| BR0108545A (pt) | 2000-02-24 | 2004-06-29 | Xcyte Therapies Inc | Estimulação e concentração simultâneas das células |
| US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| CA2438682A1 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| ES2736165T3 (es) | 2001-08-23 | 2019-12-26 | Rsr Ltd | Regiones epítopo de un receptor de tirotropina (TSH), sus usos y anticuerpos para las mismas |
| AU2002351239A1 (en) | 2001-12-04 | 2003-06-17 | Dana-Farber Cancer Institute, Inc. | Antibody to latent membrane proteins and uses thereof |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| JP4744147B2 (ja) | 2002-11-26 | 2011-08-10 | ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー | アフィニティー精製抗体を用いた甲状腺刺激ホルモン受容体自己抗体の同定 |
| WO2004087758A2 (en) | 2003-03-26 | 2004-10-14 | Neopharm, Inc. | Il 13 receptor alpha 2 antibody and methods of use |
| CU23403A1 (es) | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
| EP1646357A4 (en) | 2003-06-27 | 2007-01-10 | Diadexus Inc | PRO104 ANTIBODY COMPOSITIONS AND APPLICATION PROCEDURES |
| EP1638510B1 (en) | 2003-07-01 | 2015-09-02 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| US20050048617A1 (en) | 2003-08-18 | 2005-03-03 | Medimmune, Inc. | Humanization of antibodies |
| JP2007528723A (ja) | 2003-08-22 | 2007-10-18 | メディミューン，インコーポレーテッド | 抗体のヒト化 |
| JPWO2005035577A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | ガングリオシドｇｄ３に特異的に結合する抗体組成物 |
| AU2005235811B2 (en) | 2004-02-06 | 2011-11-03 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
| CA2568344C (en) | 2004-05-27 | 2016-01-19 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| WO2006020258A2 (en) | 2004-07-17 | 2006-02-23 | Imclone Systems Incorporated | Novel tetravalent bispecific antibody |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| EP1726650A1 (en) | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
| AU2006259536A1 (en) | 2005-06-15 | 2006-12-28 | Schering Corporation | Anti-IGF1R antibody formulations |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| JP5364870B2 (ja) | 2005-08-19 | 2013-12-11 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
| EP1960434B1 (en) | 2005-12-08 | 2012-07-11 | Medarex, Inc. | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 |
| EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| EP1996716B1 (en) | 2006-03-20 | 2011-05-11 | The Regents of the University of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
| JP5165672B2 (ja) | 2006-03-29 | 2013-03-21 | キングス カレッジ ロンドン | Ｔｓｈｒに対するアゴニスト抗体 |
| TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| WO2008040362A2 (en) | 2006-10-04 | 2008-04-10 | Københavns Universitet | Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies |
| FR2906808B1 (fr) | 2006-10-10 | 2012-10-05 | Univ Nantes | Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers |
| WO2008101234A2 (en) | 2007-02-16 | 2008-08-21 | Sloan-Kettering Institute For Cancer Research | Anti ganglioside gd3 antibodies and uses thereof |
| US7635753B2 (en) | 2007-02-19 | 2009-12-22 | Wisconsin Alumni Research Foundation | Prostate cancer and melanoma antigens |
| EP2144935A2 (en) | 2007-03-29 | 2010-01-20 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
| JP2010190572A (ja) | 2007-06-01 | 2010-09-02 | Sapporo Medical Univ | ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬 |
| CA2694990A1 (en) | 2007-07-31 | 2009-02-05 | Merck Sharp & Dohme Corp. | Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders |
| AR071891A1 (es) | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| WO2010033866A2 (en) | 2008-09-19 | 2010-03-25 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma |
| KR101589785B1 (ko) | 2009-03-10 | 2016-01-28 | 바이오젠 엠에이 인코포레이티드 | 항-ｂｃｍａ 항체 |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| MX337600B (es) | 2009-12-02 | 2016-03-11 | Imaginab Inc | Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antigeno de membrana especifico para prostata de humano (psma) y metodos para su uso. |
| WO2011076922A1 (en) | 2009-12-23 | 2011-06-30 | Synimmune Gmbh | Anti-flt3 antibodies and methods of using the same |
| AR080301A1 (es) | 2010-02-24 | 2012-03-28 | Immunogen Inc | Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos |
| WO2011159847A2 (en) | 2010-06-15 | 2011-12-22 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof |
| ES2961381T3 (es) | 2010-06-19 | 2024-03-11 | Memorial Sloan Kettering Cancer Center | Anticuerpos anti-GD2 |
| WO2012033885A1 (en) | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
| US20130273055A1 (en) | 2010-11-16 | 2013-10-17 | Eric Borges | Agents and methods for treating diseases that correlate with bcma expression |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| AU2012236068A1 (en) | 2011-04-01 | 2013-10-17 | Eureka Therapeutics, Inc. | T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2 |
| TR201815488T4 (tr) | 2011-04-08 | 2018-11-21 | Health | Anti-epidermal büyüme faktör reseptörü varyant III kimerik antijen reseptörleri ve kanser tedavisi için kullanımı. |
| US20130101599A1 (en) | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| AR086044A1 (es) | 2011-05-12 | 2013-11-13 | Imclone Llc | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos |
| UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
| SI3415531T1 (sl) | 2011-05-27 | 2023-12-29 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) - vezni proteini |
| EP2755487B1 (en) | 2011-09-16 | 2018-12-19 | Baylor College Of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| ITMO20110270A1 (it) | 2011-10-25 | 2013-04-26 | Sara Caldrer | Una cellula effettrice modificata per il trattamento di neoplasie esprimenti il disialonganglioside gd2 |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| US9439768B2 (en) | 2011-12-08 | 2016-09-13 | Imds Llc | Glenoid vault fixation |
| EP3594245A1 (en) | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| KR20140127816A (ko) | 2012-02-22 | 2014-11-04 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암의 치료에 유용한 t 세포의 지속성 집단을 생성시키기 위한 조성물 및 방법 |
| ES3065694T3 (en) | 2012-04-11 | 2026-05-07 | Us Health | Chimeric antigen receptors targeting b-cell maturation antigen |
| BR112014027166A2 (pt) | 2012-05-01 | 2017-06-27 | Genentech Inc | anticorpo, ácido nucleico, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibir proliferação e métodos de detecção. |
| LT3401400T (lt) | 2012-05-25 | 2019-06-10 | The Regents Of The University Of California | Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui |
| WO2013192294A1 (en) | 2012-06-20 | 2013-12-27 | Boston 3T Biotechnologies, Inc. | Cellular therapies for treating and preventing cancers and other immune system disorders |
| ES2937015T3 (es) | 2012-11-01 | 2023-03-23 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Anticuerpo contra CD269 (BCMA) |
| US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| ES2576126T3 (es) | 2012-12-12 | 2016-07-05 | The Broad Institute, Inc. | Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias |
| CN114634950A (zh) | 2012-12-12 | 2022-06-17 | 布罗德研究所有限公司 | 用于序列操纵的crispr-cas组分系统、方法以及组合物 |
| US9963513B2 (en) | 2013-02-05 | 2018-05-08 | Engmab Sàrl | Method for the selection of antibodies against BCMA |
| LT2958943T (lt) | 2013-02-20 | 2020-01-27 | The Trustees Of The University Of Pennsylvania | Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| EP2994530A4 (en) * | 2013-05-10 | 2016-11-16 | Whitehead Biomedical Inst | PROTEIN MODIFYING LIVING CELLS USING SORTASE |
| WO2015172800A1 (en) | 2014-05-12 | 2015-11-19 | Numab Ag | Novel multispecific molecules and novel treatment methods based on such multispecific molecules |
| MX377283B (es) * | 2013-11-21 | 2025-03-07 | Ucl Business Ltd | Célula t o nk que coexpresa un receptor antigénico quimérico (car). |
| CA2931684C (en) | 2013-12-19 | 2024-02-20 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| CN106459915A (zh) | 2014-02-04 | 2017-02-22 | 凯德药业公司 | 用于治疗b细胞恶性肿瘤和其它癌症的自体t细胞的生产方法及其组合物 |
| EP3593812A3 (en) * | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| GB201405845D0 (en) * | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| CA2945620C (en) | 2014-04-14 | 2022-12-06 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| IL296691B2 (en) | 2014-04-25 | 2023-11-01 | 2Seventy Bio Inc | MND promoter chimeric antigen receptors |
| EP3738597A1 (en) | 2014-04-25 | 2020-11-18 | Bluebird Bio, Inc. | Improved methods for manufacturing adoptive cell therapies |
| KR102526945B1 (ko) | 2014-04-30 | 2023-04-27 | 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 | Ｃｄ269에 대한 인간화 항체 |
| CN106793780B (zh) | 2014-06-06 | 2020-05-26 | 蓝鸟生物公司 | 改善的t细胞组合物 |
| MY181834A (en) | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| MX2017001079A (es) | 2014-07-24 | 2017-09-12 | Bluebird Bio Inc | Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma). |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| CA2959168A1 (en) * | 2014-09-02 | 2016-03-10 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides |
| WO2016054520A2 (en) * | 2014-10-03 | 2016-04-07 | The California Institute For Biomedical Research | Engineered cell surface proteins and uses thereof |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| EP3029068A1 (en) | 2014-12-03 | 2016-06-08 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases |
| EP3872094A3 (en) | 2014-12-05 | 2021-12-08 | Memorial Sloan Kettering Cancer Center | Antibodies targeting b-cell maturation antigen and methods of use |
| SG11201704549UA (en) | 2014-12-05 | 2017-07-28 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| EP3971210A1 (en) | 2014-12-12 | 2022-03-23 | 2seventy bio, Inc. | Composition for use in the treatment of b cell related conditions in a subject in need thereof comprisine an effector cell comrising a bcma chimeric antigen receptors |
| WO2016130598A1 (en) | 2015-02-09 | 2016-08-18 | University Of Florida Research Foundation, Inc. | Bi-specific chimeric antigen receptor and uses thereof |
| EP3270960A4 (en) | 2015-03-20 | 2018-08-08 | Bluebird Bio, Inc. | Vector formulations |
| IL310723A (en) | 2015-04-13 | 2024-04-01 | Pfizer | Therapeutic antibodies and their uses |
| TWI700298B (zh) | 2015-04-13 | 2020-08-01 | 美商輝瑞股份有限公司 | 靶向ｂ細胞成熟抗原之嵌合型抗原受體類 |
| BR112017024757A2 (pt) * | 2015-05-18 | 2018-11-13 | TCR2 Therapeutics Inc. | composições e métodos para reprogramação de tcr utilizando proteínas de fusão |
| TW202444897A (zh) * | 2015-06-25 | 2024-11-16 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體(car)、組合物及其使用方法 |
| CA2991799A1 (en) | 2015-07-15 | 2017-01-19 | Zymeworks Inc. | Drug-conjugated bi-specific antigen-binding constructs |
| MA42895A (fr) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
| AU2016302881B2 (en) | 2015-08-03 | 2022-09-15 | Bristol-Myers Squibb Company | Monoclonal antibodies against BCMA |
| US11667691B2 (en) * | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| WO2017031104A1 (en) | 2015-08-17 | 2017-02-23 | Janssen Pharmaceutica Nv | Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof |
| PT3393504T (pt) | 2015-12-22 | 2025-12-30 | Novartis Ag | Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena |
-
2018
- 2018-01-31 JP JP2019541338A patent/JP2020506700A/ja active Pending
- 2018-01-31 WO PCT/US2018/016139 patent/WO2018144535A1/en not_active Ceased
- 2018-01-31 EP EP18707168.3A patent/EP3577134A1/en not_active Withdrawn
- 2018-01-31 US US16/481,976 patent/US20190375815A1/en not_active Abandoned
- 2018-01-31 CN CN201880008928.0A patent/CN110582509A/zh active Pending
-
2023
- 2023-02-17 JP JP2023023427A patent/JP2023071774A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023516008A5 (enExample) | ||
| JP2021534783A5 (enExample) | ||
| IL295604A (en) | Methods of making chimeric antigen receptor-expressing cells | |
| KR102879284B1 (ko) | 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도 | |
| US11578115B2 (en) | Chimeric antigen receptors based on alternative signal 1 domains | |
| Kudo et al. | T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing | |
| AU2015213437B2 (en) | Trifunctional T cell-antigen coupler and methods and uses thereof | |
| JP2019513347A5 (enExample) | ||
| JP2021505131A5 (enExample) | ||
| JP2017530694A5 (enExample) | ||
| JP2020513828A5 (enExample) | ||
| RU2018134771A (ru) | Клетки, экспрессирующие множество молекул химерных антигенных рецепторов (car), и их применение | |
| KR20230148845A (ko) | 제어되고 특정한 car t 세포 활성을 위한 키메라 항원 수용체(car) 신호전달 분자 | |
| JP2017522879A5 (enExample) | ||
| CN110582509A (zh) | 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症 | |
| JP2021514631A5 (enExample) | ||
| JP2017524367A5 (enExample) | ||
| WO2014031687A1 (en) | Method and compositions for cellular immunotherapy | |
| JP2024528988A (ja) | 改変タンパク質の選択的分解のための組成物および方法 | |
| JP2021523743A (ja) | 遺伝子操作された細胞及びその応用 | |
| JP2022130557A (ja) | Ｃｄ３７を標的にするキメラ抗原受容体 | |
| EP4613781A1 (en) | Immune rejection-resistant engineered cell | |
| JP2024534417A5 (enExample) | ||
| JP2024521566A5 (enExample) | ||
| KR20230084470A (ko) | 면역 세포 기능의 향상 |